Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Premenstrual syndrome and premenstrual dysphoric disorder

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Premenstrual suicidality is an emergency

PMDD can include intense hopelessness, impulsivity, self-harm urges or suicidal thoughts, and cyclical timing does not reduce the immediate danger.

Action: Ask directly about intent, plan, means and protective factors, do not leave an unsafe person alone, and arrange urgent crisis or emergency assessment while involving trusted support with consent where possible.

Overview

Confirm a prospective cyclical symptom pattern, distinguish PMS and PMDD from premenstrual exacerbation, assess suicide risk, and use stepped psychological, serotonergic and ovulation-suppressing treatment safely.

Premenstrual disorders are defined by timing and functional impact, not by any single symptom or hormone concentration. Symptoms typically emerge after ovulation, intensify during the late luteal phase and improve within a few days of menstruation, leaving a relatively symptom-free follicular interval. They can include irritability, low mood, anxiety, affective lability, poor concentration, food craving, fatigue, bloating, breast tenderness, headache and joint or muscle discomfort. Ask which days are affected and what changes at work, study, home and in relationships.

Prospective daily ratings are central because memory is shaped by the worst days. Use a validated diary such as the Daily Record of Severity of Problems across at least two symptomatic cycles, capturing symptoms, impairment, bleeding and relevant medicines. A convincing diary shows late-luteal onset and postmenstrual remission. Do not delay urgent treatment of suicidality while waiting for two cycles; safety care and provisional symptom treatment can proceed while the pattern is documented.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Confirming cyclical disorder

A patient reports severe irritability and low mood before periods but also has some symptoms at other times. Which assessment best distinguishes PMDD from premenstrual exacerbation of another disorder?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • RCOG Green-top Guideline 48
  • RCOG managing premenstrual syndrome
  • NHS premenstrual dysphoric disorder
  • Fluoxetine 20 mg UK SmPC
  • Drospirenone 24/4 pill UK SmPC
  • Goserelin 3.6 mg UK SmPC

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

PMDD requires a more severe symptom burden than PMS, with at least five symptoms in the diagnostic framework, including at least one core mood feature such as marked affective lability, irritability, depressed mood or anxiety, and clinically significant impairment. The diagnosis also requires prospective confirmation and exclusion of another disorder. Premenstrual exacerbation is common: depression, bipolar disorder, anxiety, migraine, epilepsy, asthma, ADHD, endometriosis or chronic pain may worsen cyclically while remaining active in the follicular phase.

No blood test proves PMS or PMDD. Select pregnancy, blood count, thyroid or other tests only when history suggests an alternative. Review contraception, perimenopause, medicines, alcohol or substance use, sleep, trauma and safeguarding. Ask specifically about past hypomania or mania before an SSRI because antidepressant monotherapy can destabilise bipolar illness. Assess suicide risk on the day seen rather than assuming it will pass with menstruation.

Start with shared decisions about treatment goal, pregnancy and contraception. Regular sleep, activity, stress reduction and a balanced diet may help general health; CBT can reduce distress and improve coping. Evidence for many supplements and complementary therapies is limited, products vary and interactions occur. Avoid presenting an expensive supplement stack as safer than licensed medicines, and review high-dose vitamin B6 because neuropathy can result from excess exposure.

SSRIs act more rapidly in premenstrual disorders than in major depression and can work with continuous daily dosing or luteal-phase dosing. Fluoxetine 20 mg daily is licensed in some UK products for PMDD and is supported by both continuous and 14-day luteal regimens, with reassessment after an initial six months. Choose an SSRI around previous response, adverse effects, pregnancy plans and interactions. Nausea, sleep change and sexual dysfunction are common; serotonin toxicity, bleeding interaction and mood switching are important safety issues.

Ovulation suppression is useful when contraception is also desired or SSRI treatment is unsuitable. A combined pill containing 20 micrograms ethinylestradiol and 3 mg drospirenone in a 24 active/4 placebo schedule has evidence for PMDD symptoms, although its UK product licence is contraception. Assess migraine aura, blood pressure, smoking, thrombosis and interacting medicines. Progestogen-only methods can worsen mood in some individuals and should be monitored rather than universally avoided.

Severe refractory disease belongs in a specialist service. Transdermal oestradiol can suppress ovulation at an appropriate dose but requires endometrial progestogen with a uterus and does not provide reliable contraception at HRT doses. A GnRH agonist creates reversible ovarian suppression and can be paired with add-back hormone therapy to reduce vasomotor and bone harm. A successful suppression trial helps confirm ovarian-cycle dependence before any consideration of bilateral oophorectomy, usually with hysterectomy, which is irreversible and ends natural fertility.

Key points

  • PMS consists of distressing physical, behavioural or psychological symptoms recurring in the luteal phase and improving soon after menstruation begins, with a meaningful symptom-light interval.
  • PMDD is a severe predominantly mood-related premenstrual disorder causing major functional impairment; suicidal thoughts can occur and must be assessed directly at every relevant presentation.
  • Confirm timing prospectively with daily symptom ratings across at least two cycles before long-term treatment when safe; retrospective recall overestimates cyclicity.
  • Premenstrual exacerbation means an existing disorder worsens before menstruation but remains present at other times, and usually needs treatment of both the baseline condition and cyclical component.
  • Lifestyle support, sleep, regular activity and CBT can help, but severe symptoms should not be dismissed as a failure of self-care.
  • SSRIs are effective for severe PMS and PMDD and may be given continuously or during the luteal phase; screen for bipolar disorder, interactions and suicidality and review response.
  • A drospirenone-containing combined pill in a 24/4 regimen can be considered when contraception and ovulation suppression are wanted, after full combined-hormonal eligibility assessment.
  • Specialist ovarian suppression with transdermal oestrogen or a GnRH agonist plus add-back can test and treat refractory cyclical disease; irreversible surgery is a last option after response confirmation and fertility counselling.

Aetiology

01

Hormone-change sensitivity

Symptoms reflect abnormal central sensitivity to normal post-ovulatory steroid fluctuation rather than consistently excessive ovarian hormone concentrations.

02

Serotonergic vulnerability

Ovarian steroid metabolites interact with serotonin and GABA-related brain systems, helping explain prominent mood symptoms and rapid SSRI response.

03

Comorbid disorder interaction

Mood, anxiety, migraine, epilepsy and pain disorders may worsen with cycle change while retaining a baseline symptom burden outside the luteal phase.

Pathophysiology

  1. 1
    Ovulation creates steroid cycling

    Corpus-luteum progesterone and oestradiol rise and then fall, generating neuroactive steroid changes during the luteal phase.

  2. 2
    Central response becomes symptomatic

    Susceptible neural networks respond to ordinary hormone fluctuation with altered mood, arousal, appetite, cognition and somatic perception.

  3. 3
    Menstruation resets exposure

    Post-luteal steroid withdrawal and early follicular stability lead symptoms to remit, producing the characteristic symptom-light interval.

  4. 4
    Ovulation suppression interrupts cycling

    Combined contraception, higher-dose transdermal oestradiol or GnRH agonists can reduce cyclical signalling, though each creates separate adverse-effect and contraception considerations.

Clinical features and red flags

Cyclical timing

Symptoms arise predictably in the luteal phase, remit around or shortly after menstruation and leave a substantially symptom-light interval after the period.

Functional impairment

Missed work or study, relationship conflict, withdrawal from activities or inability to complete usual tasks separates clinically important disease from mild awareness.

PMDD mood burden

Marked irritability, lability, depressed mood, hopelessness or anxiety occurs alongside other symptoms and produces severe recurrent impairment.

Premenstrual exacerbation

A baseline psychiatric, neurological or pain disorder remains evident outside the luteal phase but predictably worsens before menstruation.

Treatment-linked change

Ovulation suppression may abolish cyclical symptoms, whereas inconsistent timing despite treatment should prompt reassessment of diagnosis, adherence and comorbidity.

Red flags requiring action

  • Current suicidal intent, a plan, access to means, recent self-harm or inability to remain safe requires urgent mental-health or emergency intervention.
  • Mania, psychosis, severe agitation or marked sleep reduction suggests bipolar or another acute psychiatric disorder and needs urgent specialist assessment before antidepressant monotherapy.
  • Symptoms present throughout the cycle without a clear symptom-free interval suggest an underlying mood, anxiety, trauma, neurodevelopmental or medical disorder rather than isolated PMS.
  • New heavy, intermenstrual or postcoital bleeding, pelvic mass symptoms or severe non-cyclical pain requires a separate gynaecological pathway.
  • Focal neurological symptoms, first severe migraine with aura or thromboembolic symptoms during hormonal treatment require urgent assessment and treatment review.

Investigations

  1. 01
    Prospective daily symptom recordFirst step
    Why
    Confirm timing, severity, impairment and a symptom-light follicular interval over at least two cycles.
    Interpretation and limitations
    Late-luteal rise with prompt postmenstrual improvement supports PMS or PMDD; persistent symptoms across the month suggest another disorder or premenstrual exacerbation.
  2. 02
    Structured mental-health assessment
    Why
    Assess suicide risk, depression, anxiety, bipolar features, trauma, substance use and safeguarding.
    Interpretation and limitations
    Immediate risk determines urgent care; a history of mania or hypomania changes antidepressant choice and warrants specialist input.
  3. 03
    Pregnancy, thyroid and blood count when indicated
    Why
    Investigate plausible reproductive, endocrine or haematological mimics from the history.
    Interpretation and limitations
    Normal tests do not prove PMDD; abnormal results are treated as their own disorders while prospective cycle ratings continue if symptoms remain cyclical.
  4. 04
    Treatment response diary
    Why
    Measure change after an SSRI, combined pill or ovarian-suppression trial against the pretreatment pattern.
    Interpretation and limitations
    Reduced luteal symptoms and improved function supports effectiveness; global sedation without functional improvement is not a successful outcome.
  5. 05
    Bone and cardiovascular assessment for suppression
    Why
    Establish safety before prolonged GnRH-agonist or systemic hormone treatment.
    Interpretation and limitations
    Bone risk, blood pressure, migraine, thrombosis and uterine status determine add-back choice and whether suppression remains acceptable.

Differential diagnosis

01

Major depression or anxiety

Symptoms persist through the follicular phase even if they intensify premenstrually, requiring baseline mental-health treatment as well as cycle-aware care.

02

Bipolar disorder

Past hypomania, mania, reduced need for sleep or episodic activation changes antidepressant safety and warrants psychiatric assessment.

03

Perimenopause

Changing cycle length, vasomotor symptoms and less predictable hormonal fluctuation can mimic or aggravate a previous premenstrual pattern.

04

Thyroid or anaemia-related symptoms

Fatigue, cognitive change, palpitations and low mood may follow endocrine or haematological disease and require targeted testing from clinical clues.

05

Endometriosis or menstrual migraine

Cyclical pain or neurological symptoms may centre on menstruation but follow a disease-specific pattern rather than the broad luteal PMS constellation.

Management

01ConfirmationProve the cycle relationshipFirst stepRecurrent premenstrual physical or mood symptoms affect daily life.+
  1. 1Assess current safety, baseline psychiatric and medical disorders, contraception, medicines and the exact onset and offset of symptoms.
  2. 2Record daily symptoms, impairment and bleeding for at least two cycles using a validated tool, unless urgent care must proceed immediately.
  3. 3Classify PMS, PMDD or premenstrual exacerbation from prospective pattern and severity, then agree a measurable treatment goal.
02Initial treatmentCombine coping and evidence-based therapyA clinically important cyclical disorder is confirmed or strongly suspected while monitoring continues.+
  1. 1Offer sleep, activity and stress support plus CBT where available, without making lifestyle change a prerequisite for medical care.
  2. 2For severe mood symptoms, offer an SSRI continuously or in the luteal phase after bipolar, suicide, interaction and pregnancy review.
  3. 3When contraception is wanted, consider an eligible drospirenone 24/4 combined pill and review mood, bleeding and vascular safety.
03Urgent mood riskTreat danger before diagnostic completenessThe patient reports suicidal thinking, self-harm, mania, psychosis or inability to remain safe.+
  1. 1Complete an immediate risk assessment, involve urgent mental-health or emergency services and remove access to means where safely possible.
  2. 2Include trusted support with consent, provide crisis contacts and arrange active follow-up rather than relying on the anticipated period date.
  3. 3Revisit cyclical diagnosis and longer-term prevention after immediate safety and any underlying mood disorder are addressed.
04Refractory symptomsTest reversible ovarian suppressionProspectively confirmed severe symptoms continue despite tolerated SSRI, CBT or eligible combined hormonal treatment.+
  1. 1Refer to a gynaecology or specialist hormone service and reassess adherence, bipolar disorder, trauma, migraine and premenstrual exacerbation.
  2. 2Use specialist transdermal oestradiol suppression or a time-limited GnRH-agonist trial with uterine and bone-protective add-back as appropriate.
  3. 3Discuss irreversible surgery only after clear suppression response, completed fertility plans, surgical counselling and a workable long-term HRT strategy.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Reduces severe affective, behavioural and physical premenstrual symptoms through serotonergic modulation.

Fluoxetine

Give 20 mg orally once daily either continuously or for 14 days during the luteal phase; the current PMDD SmPC advises reassessment after an initial six months.

Screen for bipolar disorder and suicide risk; review nausea, insomnia, sexual dysfunction, bleeding, hyponatraemia, serotonin interactions and the long half-life when switching or planning pregnancy.

Provides contraception and suppresses ovulation with evidence for improvement in PMDD symptoms in a 24/4 regimen.

Ethinylestradiol 20 micrograms with drospirenone 3 mg

Take one active oral tablet daily for 24 days followed by one placebo tablet daily for four days, repeating without an extended hormone-free interval.

The UK licence is contraception; assess blood pressure, migraine aura, smoking, venous or arterial thrombosis, liver or renal disease, potassium-raising medicines and interactions.

Creates reversible ovarian suppression for prospectively confirmed severe premenstrual symptoms that have not responded to simpler treatment.

Goserelin specialist suppression

Give a 3.6 mg subcutaneous implant every 28 days for a time-limited specialist trial, adding an individually selected oestrogen-progestogen regimen when suppression continues.

Use is specialist and not licensed specifically for PMS; exclude pregnancy, protect bone and endometrium, monitor mood and vasomotor effects, and provide non-hormonal contraception if needed.

Complications

01

Suicide and self-harm

Severe cyclical hopelessness, impulsivity and mood disturbance can produce acute danger that requires ordinary emergency risk management.

02

Occupational and relationship harm

Repeated predictable impairment can cause absence, reduced performance, conflict, isolation and loss of confidence across many cycles.

03

Medicine adverse effects

SSRIs can cause sexual or mood effects, combined pills add vascular risk and ovarian suppression can reduce bone density without add-back.

04

Irreversible fertility loss

Bilateral oophorectomy ends natural oocyte fertility and creates permanent surgical menopause requiring a carefully planned replacement strategy.

Monitoring and follow-up

  • Continue daily ratings for two to three cycles after each treatment change so symptom benefit and functional recovery are measured against baseline.
  • Review suicide risk and mood switching early after starting or changing an antidepressant and whenever the premenstrual high-risk window approaches.
  • Check blood pressure, bleeding, migraine and thromboembolic symptoms during combined hormonal treatment and revisit contraceptive eligibility after health changes.
  • During GnRH-agonist treatment, monitor vasomotor symptoms, mood, bone risk and add-back adherence, with duration and DXA decisions made by the specialist service.
  • Reassess the diagnosis when treatment fails across the whole cycle, because premenstrual exacerbation, bipolar disorder, chronic pain or perimenopause may require a different plan.

Special situations

Prospective data changes diagnosis

Many people who recall exclusively premenstrual symptoms show important symptoms throughout the month when daily ratings are collected.

SSRIs can work intermittently

Rapid premenstrual response permits luteal-phase dosing for some patients, unlike the continuous weeks usually required to treat major depression.

Suppression can be diagnostic

A marked response to reversible GnRH-agonist ovarian suppression supports true cycle dependence before irreversible ovarian surgery is considered.

Add-back is not treatment failure

Carefully selected oestrogen and progestogen can reduce bone and vasomotor harm while maintaining ovarian suppression, though progestogen sensitivity needs monitoring.

Cyclical risk remains real risk

Predictable remission after menstruation does not make suicidal intent safe to manage at home during the symptomatic phase.

Common pitfalls

  1. 01

    Diagnosing PMDD from retrospective symptom recall without prospective cycle ratings when the situation is safe enough to document.

  2. 02

    Calling continuous depression PMS because it becomes worse before menstruation.

  3. 03

    Starting an SSRI without asking about past mania, current suicidality, interactions and pregnancy intention.

  4. 04

    Prescribing a drospirenone combined pill without full thrombotic, migraine and blood-pressure assessment.

  5. 05

    Using prolonged GnRH suppression without add-back, bone planning or reliable contraception advice.

  6. 06

    Offering bilateral oophorectomy without a successful reversible suppression trial and comprehensive fertility and HRT counselling.